Sentiment Trading

Aytu BioPharma reported strong Q3 2025 financials, with $18.5 million in revenue and $4.0 million in net income, exceeding expectations and marking a 32% year-over-year revenue growth.

Aytu BioPharma Inc. reported a 32% increase in net revenue and a significant turnaround in net income for its Q3 2025, driven by strong performances across its product portfolios.